Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors.
Adult
Aged
Cell Adhesion Molecule-1
/ biosynthesis
Cystadenocarcinoma, Serous
/ pathology
Cystadenoma, Serous
/ pathology
Female
Humans
Immunohistochemistry
Lymphatic Metastasis
/ pathology
Middle Aged
Neoplasm Staging
Ovarian Neoplasms
/ pathology
Receptor, ErbB-2
/ biosynthesis
STAT3 Transcription Factor
/ biosynthesis
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
26 Feb 2021
26 Feb 2021
Historique:
received:
22
08
2020
accepted:
16
11
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
17
3
2021
Statut:
ppublish
Résumé
The subtypes of serous ovarian tumors (SOTs), including benign serous cystadenoma, serous borderline tumor (SBT), low-grade serous ovarian carcinoma (LGSC), and high-grade serous ovarian carcinoma (HGSC), remain poorly understood. Herein, we aimed to characterize the cell adhesion molecule 1 (CADM1)/signal transducer and activator of transcription 3 (STAT3)/human epidermal growth factor receptor 2 (HER2) axis and identify its clinical significance in patients with serous cystadenoma, SBT, LGSC, and HGSC.The immunohistochemical expression of CADM1, HER2, and STAT3 was assessed in 180 SOT specimens, and its association with clinical data was determined.High levels of CADM1 expression were detected in 100% of serous cystadenomas and 83.33% of SBTs, while a loss of CADM1 expression was observed in 44% of LGSCs and 72.5% of HGSCs. Relative to the levels in benign cystadenomas and SBTs, higher levels of HER2 and STAT3 expression were observed in LGSCs and aggressive HGSCs. Furthermore, the expression profile of the CADM1/HER2/STAT3 axis was significantly associated with histologic type, International Federation of Gynecology and Obstetrics stage, and lymph node metastasis in patients with SOT.Our study identified the changes in the CADM1/HER2/STAT3 axis that were closely associated with the clinical behavior of SOTs. These molecular data may provide new insights into SOT carcinogenesis and aid in the diagnosis and treatment of patients with SOT.
Identifiants
pubmed: 33663040
doi: 10.1097/MD.0000000000023777
pii: 00005792-202102260-00003
pmc: PMC7909124
doi:
Substances chimiques
Cell Adhesion Molecule-1
0
STAT3 Transcription Factor
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23777Subventions
Organisme : Health and Family Planning Commission of Hunan Province (CN)
ID : C2019105
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061.
Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719–25.
Dabi Y, Huchon C, Ouldamer L, et al. Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival. J Transl Med 2020;18:134.
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–53.
Ricci F, Affatato R, Carrassa L, et al. Recent insights into mucinous ovarian carcinoma. Int J Mol Sci 2018;19:1569.
Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 2015;33:2345–52.
Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012;25:625–36.
Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011;42:918–31.
Vallath S, Sage EK, Kolluri KK, et al. CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity. Sci Rep 2016;6:24006.
Momose K, Minami A, Shimono Y, et al. miR-214 and hypoxia down-regulate Necl-2/CADM1 and enhance ErbB2/ErbB3 signaling. Genes Cells 2013;18:195–202.
Mao X, Seidlitz E, Ghosh K, et al. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res 2003;63:7979–85.
Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496–504.
Ho CL, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915–8.
Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547–53.
Faraji F, Pang Y, Walker RC, et al. Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet 2012;8:e1002926.
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.
Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95–8.
Silver DL, Naora H, Liu J, et al. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004;64:3550–8.
Lee HJ, Zhuang G, Cao Y, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014;26:207–21.
Gebhart G, Flamen P, De Vries EG, et al. Imaging diagnostic and therapeutic targets: human epidermal growth factor receptor 2. J Nucl Med 2016;57: (Suppl 1): 81S–8S.
Rousseau C, Goldenberg DM, Colombié M, et al. Initial clinical results of a novel immuno-PET theranostic probe in human epidermal growth factor receptor 2-negative breast cancer. J Nucl Med 2020;61:1205–11.
Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 2018;15:234–48.
Huynh J, Chand A, Gough D, et al. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer 2019;19:82–96.